ELX-02 is in the early stages of clinical development focusing ... and the quotation of the Company’s common stock on …
KTVN15d
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an …
Following the reverse stock split and post-acquisition ... Eloxx’s lead product candidate, ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. Eloxx was founded in 2013 and maintains offices in …
Wesfarmers Limited (ASX:WES) and Baby Bunting Group Ltd (ASX:BBN) are among December's top stock picks.
ELX-02 is a fifth-generation designer aminoglycoside optimized ... and the quotation of the Company's common stock
"I believe Eloxx has tremendous potential and I look forward to the continued advancement of ELX-02 across a wide …
El Oro swung into the black in the year to the end of June with a pre-tax profit of £7,426,687 compared with a loss of £615,636 last time. The group's net assets stood at £55,680,730 or 88.1p per share at the end of June - up from …
Under the terms of the agreement, Eloxx shareholders will receive shares of Sevion’s common stock reflecting 70% of Sevion’s share ... Eloxx's lead compound, ELX-02, provides unique opportunity to potentially be the first disease …
Under the terms of the agreement, Eloxx shareholders will receive shares of Sevion’s common stock reflecting …